10 slides from Agenus's conference presentation, Jan 21, 2023
Slide 1: Results from a phase 1a/1b study of botensilimab plus balstilimab in MSS CRC
agenus Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC) Authors: Anthony B. El-Khoueiry, MD’, Marwan G. Fakih, MD2, Michael S
Slide 2: Active in 'Cold' and IO Refractory Tumors
Active in ‘Cold’ and IO Refractory Tumors genus Fc-enhanced CTLA-4 Inhibitor <= @ | APCINK a \ » FoyRIIIA # CTLA-4 T Cell PN Active in ‘cold’ and IO refractory tumors*? * >300 patients treated across 4 trials * 4 T cell priming, expansion, memory? * 4 Frequency of activated APCs * 4 Treg depletion *
Slide 3: C-800 Study Design: MSS CRC Cohort
C-800 Study Design: MSS CRC Cohort NCT03860272: First-in-human trial of botensilimab + Key Eligibility for CRC * Refractory Metastatic CRC * MSS by local assessment * Prior lO allowed * Thili< 1.5 x IULN * AST/ALT < 2.5 x IULN Evaluable Population Treated with 1 or 2 mg/kg bot + bal as of 29 August
Slide 4: Patient Characteristics
Patient Characteristics Characteristic Age, median (range) Sex, n (%) Female Male ECOG PS at baseline, n (%) 0 1 Prior lines of therapy, n (%) Median (range) Overall (N=70)* 57 (25-83) 40 (57) 30 (43) 28 (40) 42 (60) 4 (1-10) Characteristic Prior immunotherapy, n (%) Botensilimab dose, n (%) 1 mg/kg
Slide 5: Deep Objective Responses
Deep Objective Responses ox Ss Change in Sum of Target Lesions (%) ° 90 | -100 4 Efficacy ORR®, % (95% Cl) BOR, n (%) CR PR sD DCR (CR + PR + SD), % (95% Cl) Median, OS (95% Cl) Median PFS, months (95% Cl) Median F/U, months (Min, Max) “Includes unconfirmed responses. co Resected target lesions show
Slide 6: Durable Objective Responses
Durable Objective Responses Change in Sum of Target Lesions (%) 20% Tumor Growth 30% Tumor Reduction genus Responder Characteristics (n=16) 11/16 ongoing responses 3 with prior I-O (all refractory) 1/13 TMB >10 mut/Mb 1/8 PD-L1 positive (21%) 11 RAS mut “Includes unconfirmed responses Resected targe
Slide 7: Overall Survival
Overall Survival agenus Efficacy evaluable population, N=70 Overall No Active Liver Mets Active Liver Mets 10- Median, OS (95% Cl) —_ NR (10.3-NR) NR (NR-NR) 9.4 (6.1-NR) 09-4 12-month, OS (95% Cl) 63 (46-76) 81 (66-90) 40 (17-62) 08-4 oo 2 2 2 2 J 0.77 06 oo 2 2 2 0.5 4 0.44 0.3 4 —-— NodActive Liv
Slide 8: Safety Profile
Safety Profile All TRAEs of Any Grade in 215% of All Patients ALL n (%) GRADE ANY TRAE 64 (91) GASTROINTESTINAL IM diarrhea/colitis* 30 (43) Nausea 16 (23) CONSTITUTIONAL Fatigue 24 (34) Decreased appetite 19 (27) Chills 15 (21) Pyrexia 16 (23) GRADE 3 28 (40) 14 (20) 1 (1) 3 (4) 3 (4) * Immune-medi
Slide 9: Summary & Future Directions
Summary & Future Directions genus ¢ Botensilimab is a CTLA-4 antibody with enhanced binding to activating Fc receptors enabling innate and adaptive immune activation ¢ Durable objective responses in heavily pre-treated patients with MSS CRC ¢ Manageable safety profile ¢ Favorable overall survival: 1